Research Paper Volume 13, Issue 24 pp 26180—26200
NAP1L1 promotes proliferation and chemoresistance in glioma by inducing CCND1/CDK4/CDK6 expression through its interaction with HDGF and activation of c-Jun
Figure 2. Suppressing NAP1L1 inhibits glioma cell proliferation and chemoresistance. (A) NAP protein level was measured by western blot in U87 and LN229 cells transfected with shNC or shNAP. GAPDH was used as a loading control. With efficient knockdowns from shNAP was separately detected by RT-PCR assays. (B) NAP protein level was measured by western blot in U87 and LN229 cells transfected with siNC or siNAP. GAPDH was used as a loading control. MTT assay (C), clone formation assay (D) after NAP1L1 knockdown. Gross morphology of tumors (E) and tumor weight statistics (F) from the indicated groups (n = 4 per group). (G) Tumor volume statistics for each mouse group (n = 4 per group). (H) Dose-response curves of U87 and LN229 treated with shNAP and shNC respectively following treatment with DDP for 48 h. Data are presented as the mean ± SD for three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.